381 related articles for article (PubMed ID: 22331945)
21. A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study.
Grignani G; Palmerini E; Stacchiotti S; Boglione A; Ferraresi V; Frustaci S; Comandone A; Casali PG; Ferrari S; Aglietta M
Cancer; 2011 Feb; 117(4):826-31. PubMed ID: 20925044
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.
Chugh R; Dunn R; Zalupski MM; Biermann JS; Sondak VK; Mace JR; Leu KM; Chandler WF; Baker LH
J Clin Oncol; 2005 May; 23(15):3597-604. PubMed ID: 15908670
[TBL] [Abstract][Full Text] [Related]
23. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
Goerres GW; Stupp R; Barghouth G; Hany TF; Pestalozzi B; Dizendorf E; Schnyder P; Luthi F; von Schulthess GK; Leyvraz S
Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):153-62. PubMed ID: 15690223
[TBL] [Abstract][Full Text] [Related]
24. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of imatinib in unresectable hepatocellular carcinoma.
Lin AY; Fisher GA; So S; Tang C; Levitt L
Am J Clin Oncol; 2008 Feb; 31(1):84-8. PubMed ID: 18376233
[TBL] [Abstract][Full Text] [Related]
26. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
Tamborini E; Miselli F; Negri T; Lagonigro MS; Staurengo S; Dagrada GP; Stacchiotti S; Pastore E; Gronchi A; Perrone F; Carbone A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2006 Dec; 12(23):6920-8. PubMed ID: 17145809
[TBL] [Abstract][Full Text] [Related]
27. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
Blay JY; Le Cesne A; Ray-Coquard I; Bui B; Duffaud F; Delbaldo C; Adenis A; Viens P; Rios M; Bompas E; Cupissol D; Guillemet C; Kerbrat P; Fayette J; Chabaud S; Berthaud P; Perol D
J Clin Oncol; 2007 Mar; 25(9):1107-13. PubMed ID: 17369574
[TBL] [Abstract][Full Text] [Related]
28. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.
Kérob D; Porcher R; Vérola O; Dalle S; Maubec E; Aubin F; D'Incan M; Bodokh I; Boulinguez S; Madelaine-Chambrin I; Mathieu-Boue A; Servant JM; de Kerviler E; Janin A; Calvo F; Pedeutour F; Lebbe C
Clin Cancer Res; 2010 Jun; 16(12):3288-95. PubMed ID: 20439456
[TBL] [Abstract][Full Text] [Related]
29. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
[TBL] [Abstract][Full Text] [Related]
30. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
[TBL] [Abstract][Full Text] [Related]
31. A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer.
Gharibo M; Patrick-Miller L; Zheng L; Guensch L; Juvidian P; Poplin E
Pancreas; 2008 May; 36(4):341-5. PubMed ID: 18437079
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
[TBL] [Abstract][Full Text] [Related]
33. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
34. Response to imatinib plus sirolimus in advanced chordoma.
Stacchiotti S; Marrari A; Tamborini E; Palassini E; Virdis E; Messina A; Crippa F; Morosi C; Gronchi A; Pilotti S; Casali PG
Ann Oncol; 2009 Nov; 20(11):1886-94. PubMed ID: 19570961
[TBL] [Abstract][Full Text] [Related]
35. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy and safety of imatinib in treatment of 151 chronic myeloid leukemia patients].
Zhou L; Wang AH; Wang L; You JH; Li JM; Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):13-7. PubMed ID: 18512309
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of imatinib in patients with small cell lung cancer.
Johnson BE; Fischer T; Fischer B; Dunlop D; Rischin D; Silberman S; Kowalski MO; Sayles D; Dimitrijevic S; Fletcher C; Hornick J; Salgia R; Le Chevalier T
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5880-7. PubMed ID: 14676110
[TBL] [Abstract][Full Text] [Related]
40. Phase II study on lapatinib in advanced EGFR-positive chordoma.
Stacchiotti S; Tamborini E; Lo Vullo S; Bozzi F; Messina A; Morosi C; Casale A; Crippa F; Conca E; Negri T; Palassini E; Marrari A; Palmerini E; Mariani L; Gronchi A; Pilotti S; Casali PG
Ann Oncol; 2013 Jul; 24(7):1931-1936. PubMed ID: 23559153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]